Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 2,543,082 shares, a growth of 3.6% from the April 30th total of 2,454,083 shares. Approximately 8.2% of the company’s sha
Countless workers look forward to retirement and the opportunity to do what they want with their time. But if you're not careful, retirement could end up being nothing more than an extended period of financial stress. Here are a few moves that could leave you distraught and cash-strapped during
S&P Global Market Intelligence’s Jeffrey Loo explains why he’s maintaining his Buy rating on Valeant Pharmaceuticals International (VRX) following reports it had rejected a takeover bid earlier this year:
According to unconfirmed reports, including the Wall Street Journal,Valeant rejected an unsolicited joint takeover bid from Takeda Pharmaceutical, the largest....More>>>
The owner of the Los Angeles Times is in talks to sell the paper to a local biotech billionaire, the latest twist in a chaotic few months for the nation’s largest metro newspaper, sources familiar with the matter told CNNMoney.
Michael Ferro, who controls the paper’s parent company Tronc, is negotiating with Patrick Soon-Shiong, a Tronc investor and physician who has been dubbed....More>>>
Exxon Mobil Corporation (NYSE:XOM) stock holders are probably still shaking their heads in disbelief. Exxon Mobil stock barely moved despite what looked like a very strong first-quarter earnings report earlier this month. Chevron Corporation (NYSE:CVX) and BP plc (ADR) (NYSE:BP) completed the trifecta, with only ConocoPhillips (NYSE:COP) disappointing.
On the surface, Valeant Pharmaceuticals (VRX) has an intrinsic value of over $50 a share but very recently, the market is considering more bearish scenarios. Instead of pointing to the debt reduction ahead of schedule, revenue improvements at both Salix and B+L, shareholders should consider the upcoming catalysts ahead.
Valeant launched SILIQs (brodalumab) in July. The drug, which treats....More>>>
Is a stock market pullback on the way? Maybe. And even if not now, it’s inevitable that the market will take a breather at some point in the future.
Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN),....More>>>
Let’s get right to it, Village Farms International (OTCQX:VFFIF or TSE:VFF) has the potential to be the low cost producer in the Canadian medical marijuana industry. This investment is based on stages of development, which I plan to explore with readers and let you know, in likely the most transparent way possible, how I plan to “play” this player in this promising industry.
Jimmy Buffett has restaurants, a line of beer, adventure vacations, casinos, clothing, resorts, radio and television assets as well as salad dressings, margarita salt and spicy frozen shrimp. Up next? Retirement communities.
It was just a matter of time until the man who built an empire on Margaritaville, a song about drinking too much and bumming around in a beach town, would figure out....More>>>
Teladoc (NYSE:TDOC) hit a new 52-week high and low during mid-day trading on Thursday . The company traded as low as $50.70 and last traded at $50.60, with a volume of 673212 shares changing hands. The stock had previously closed at $49.85.
Revenues increased 30% YoY to INR14.7b (est INR14.3b) led by tonnage growth of 24.5% YoY to 67.7kMT (est. of 67.2kMT) and realizations growth of 4.7% YoY (flat QoQ) to INR213.5k/ton (in-line). EBITDA margin contracted 150bp QoQ (flat YoY)
Equities research analysts expect that Euronet Worldwide (NASDAQ:EEFT) will post earnings per share (EPS) of $1.32 for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Euronet Worldwide’s earnings. Euronet Worldwide reported earnings of $1.09 per shar
Shares of Callon Petroleum (NYSE:CPE) traded down 5% during mid-day trading on Thursday . The stock traded as low as $12.47 and last traded at $12.48. 6,420,719 shares traded hands during mid-day trading, an increase of 45% from the average session volume of 4,431,217 shares. The stock had previ
Shares of Box (NYSE:BOX) have been given an average recommendation of “Buy” by the twenty research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and two